论文部分内容阅读
Nedocromil sodium(NED)作用与色苷酸钠(SCG)类似,是一种新型的抗哮喘药物,具有稳定粘膜表面肥大细胞,抑制多种变应原引起的支气管收缩的作用.虽然体内外试验结果均提示其疗效优于SCG,但未作定量比较。为此,作者在8例特应性哮喘病人中,比较了吸入雾化安慰剂、SCG 和NED 对抑制一磷酸腺苷(AMP)诱发支气管收缩的疗效.8例患者年龄21～32岁(平均25岁)试验前3周停用 SCG,前12小时停用β_2受体激动剂和皮质激素。研究结果显示,预先吸入 SCG 和 NED 对吸入 AMP 所致的 FEV_1或(?)max30下降有明显的抑制作用,而且NED 强于 SCG.在应用安慰剂后,降低 FEV_1 20%(PD_(20)FEV_1)和(?)max30 40%(PD_(40)(?)max30),所用 AMP 的激发剂量分别为4.9(0.3～14.2)和1.8(0.1～8.4)μmol,与试验前 PD_(20)FEV_1AMP 的激发剂量3.33μmol 相比,无明显差异,而预
Nedocromil sodium (NED) acts as a novel anti-asthmatic drug similar to sodium nitroprusside (SCG) and has the effect of stabilizing mucosal mast cells and inhibiting the bronchoconstriction induced by various allergens. Although in vitro and in vivo results All suggest that its efficacy is better than SCG, but not for quantitative comparison. To this end, the authors compared the effects of inhaled nebulized placebo, SCG and NED on inhibition of AMP-induced bronchoconstriction in 8 patients with atopic asthma.8 years of age, 21 to 32 years (mean 25 years old) SCG was discontinued 3 weeks prior to the test, β 2 receptor agonists and corticosteroids were discontinued in the first 12 hours. The results showed that pre-inhalation of SCG and NED significantly inhibited the decrease of FEV_1 or (?) Max30 induced by inhaled AMP, and NED was stronger than SCG. After placebo, the FEV_1 20% (PD 20 FEV_1 ) And max30 40% (PD 40 (max30), respectively). The doses of AMP used were 4.9 (0.3-14.2) and 1.8 (0.1-8.4) Excitation dose 3.33μmol compared to no significant difference, while pre-